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Introduction
IL-1 is an important cytokine involved in acute and
chronic inflammation in a complex network of signaling
molecules. The three known constituents of the IL-1 gene
family are IL-1α, IL-1β and IL-1 receptor antagonist 
(IL-1RA), which all bind to the IL-1 receptor with similar
affinity (1). Although IL-1α remains in the cytosol or is
expressed at cell membranes, IL-1β is released after pro-
teolytic cleavage and is therefore more prominent in
propagation of the inflammatory process. IL-1RA is pres-
ent in both intracellular and secreted forms (2). All three
IL-1 constituents show complex regulation on the tran-
scriptional, translational, and post-translational level, an
important facet that has to be considered in interpreta-
tion of studies demonstrating altered signal or protein
expression in animal or human diseases (3).
IL-1 is involved in various disorders of the lung. Most
investigations focus on proinflammatory effects of 
IL-1; however, there is increasing evidence that IL-1 also
elicits potent profibrotic responses. A number of
human and animal studies have revealed the presence
of IL-1β in chronic inflamed tissues and in tissues
undergoing fibrogenesis, with accumulation of myofi-
broblasts and matrix deposition (1, 4–7). Inhibition of
IL-1β at the initiation of animal models of fibrosis
caused attenuation of the disease (8), suggesting a
causative link between cytokines involved in the acute
phase of inflammation, such as IL-1, and the conver-
sion to chronic inflammation and fibrosis.
Although the role of IL-1 in tissue repair and fibrosis
is uncertain, the importance of TGF-β1 in these process-
es is well recognized (9, 10). TGF-β1 is one of the key
cytokines in scar formation and acts at different levels to
increase lung collagen deposition. It is chemotactic for
fibroblasts and promotes their transformation to myofi-
broblasts, induces the synthesis of matrix proteins and
glycoproteins, and inhibits collagen degradation. We
have previously shown, in a gene-transfer model similar
to that described here, that transient overexpression of
active TGF-β1 causes severe progressive fibrotic reac-
tions in the lung (11). Other, moderately profibrotic
cytokines such as GM-CSF and TNF-α mediate fibrotic
responses likely through TGF-β (12–14).
We have used a recombinant replication-deficient ade-
novirus vector to transfer and overexpress the gene for
human IL-1β for a transient but prolonged period (7–10
days) in rodent lung. This extended expression of IL-1β
elicits acute alveolar and parenchymal damage with sub-
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sequent induction of TGF-β expression and progressive
interstitial fibrogenesis over the period of the next 60 days
to termination. Matrix deposition and accumulation of
myofibroblasts appear similar to those seen in human
pulmonary fibrosis. These data complement our previous
results with active TGF-β in the lung (11) and contrast
with the acute inflammation but minimal tissue damage
and lack of chronic changes seen with lung gene transfer
of TNF-α (12), the other suspected acute inflammatory
cytokine. These data indicate that IL-1β plays an immedi-
ate and direct role in the induction of acute and chronic
inflammation and should be considered a valid target for
therapeutic intervention in diseases associated with fibro-
sis and tissue remodeling, such as idiopathic pulmonary
fibrosis, asthma, liver cirrhosis, and renal fibrosis.
Methods
Recombinant adenovirus. The construction of adenoviral
vectors is described in detail elsewhere (15). For con-
struction of AdhIL-1β, human IL-1β cDNA (in
pGEM3Z vector, a gift from British Biotech Pharma-
ceuticals Ltd., Oxford, United Kingdom) was cloned
into a shuttle vector with a human cytomegalovirus
promoter and cotransfected on 293 cells with a plasmid
containing E1- to E3-deleted type 5 adenoviral genome.
The resulting replication-deficient virus was amplified
and purified by CsCl gradient centrifugation and 
PD-10 Sephadex chromatography, and finally plaque
titered on 293 cells. The vector was checked for integri-
ty of viral DNA (by restriction digest and Southern
blot) and expression of the desired protein (by Western
blot). Control vectors (AdDL70) with no insert in the
E1 region were produced in the same way.
Animal treatment. Female Sprague-Dawley rats (Charles
River Laboratories, Montreal, Quebec, Canada), weigh-
ing 200–250 g, were housed under special pathogen-free
conditions. Rodent laboratory food and water was pro-
vided ad libitum. The animals were treated in accordance
to the guidelines of the Canadian Council of Animal
Care. All animal procedures were performed with inhala-
tion anesthesia with isoflurane (MTC Pharmaceuticals,
Cambridge, Ontario, Canada). A total of 5 × 108 plaque-
forming units (pfu) of AdhIL-1β or AdDL70 was admin-
istered intratracheally in a volume of 300 µl PBS after
minor surgical preparation. One group of animals
received PBS only (n = 4). AdhIL-1β–treated rats were sac-
rificed by abdominal aortic bleeding at days 2 (n = 3), 7
(n = 4), 14 (n = 3), 21 (n = 4), 42 (n = 3), and 60 (n = 3).
AdDL70-treated control animals were sacrificed at days
2 (n = 2), 7 (n = 3), 14 (n = 2), and 21 (n = 3).
Bronchoalveolar lavage (BAL) was performed as
described previously (11). BAL fluid was processed
for cell counts and stored until determination of
cytokine concentration. The right main bronchus
was tied; the lung was removed, rinsed in PBS again,
and frozen immediately in liquid nitrogen. Tissue
samples were stored at –70°C until further process-
ing. The left lung was inflated with and fixed in 10%
formalin for histological examination.
Determination of cytokine levels in BAL fluid. Human IL-1β
(Amersham Pharmacia Biotech, Piscataway, New Jersey,
USA) and rat IL-1β, rat TNF-α, rat IL-6, human PDGF-
AB, and human TGF-β1 (all R&D Systems, Minneapolis,
Minnesota, USA) were measured using ELISA according
to manufacturers’ recommendations. TGF-β1 measured
by ELISA was latent plus active TGF-β after acid activa-
tion. The cross reactivity between human and rat IL-1β in
the assays used was less than 2%. The PDGF and TGF-β
ELISA used detects PDGF and TGF-β across species.
TGF-β bioassay. Bioactive TGF-β was detected with an
established bioassay using mink lung epithelial cells
(MLECs) with a stable transfection of the human plas-
minogen-activator-inhibitor–1 gene fused to the firefly
luciferase reporter gene (16). Standards for TGF-β1
were generated adding recombinant human TGF-β to
the medium of MLECs (10–500 pg/ml; R&D Systems).
Luciferase activity was measured with (D)-luciferin
(Luciferase Assay System; Promega Corp., Madison,
Wisconsin, USA) and multiplate luminometer (Tropix
TR717; Applied Biosystems, Foster City, California,
USA). Data are presented in relative light units (RLUs).
Serum cysteine protease inhibitor. Rat serum was ana-
lyzed for the acute-phase protein, rat α1-cysteine pro-
tease inhibitor, by immunoelectrophoresis as
described previously (17). Rat serum samples were elec-
trophoresed for 16 hours through a 1% agarose gel
containing rabbit anti–rat α1-cysteine protease
inhibitor serum in barbital buffer (pH 8.6). The gel was
transferred to Gel Bond film (FMC Bioproducts, Rock-
land, Maine, USA) and stained with Coomassie bril-
liant blue. Amounts of α1-cysteine protease inhibitor
were extrapolated using rat serum standard curves and
expressed as milligrams per milliliter.
Histology and immunohistochemistry. After fixation in
10% buffered formalin for 24 hours, longitudinal sec-
tions of the lung were paraffin embedded, sectioned,
and stained with hematoxylin and eosin and Masson-
trichrome. Immunohistochemistry was performed to
stain cells and structures positive for α-smooth mus-
cle actin (α-SMA) and fibronectin. Sections (3 µm)
were cut on aptex-coated slides and were deparaf-
finized in xylene followed by 100% ethanol and then
placed in a freshly prepared methanol H2O2 solution
for 30 minutes to block endogenous peroxidase activ-
ity. After hydration to water with graded alcohol, the
sections were placed in 0.05M Tris buffer saline (TBS;
pH 7.6). Immunohistochemistry was carried out with
antibodies against α-SMA and fibronectin (DAKO
Corp., Carpinteria, California, USA). For α-SMA
immunohistochemistry, sections were blocked with
1% normal swine serum (NSS) in TBS for 20 minutes
followed by incubation in 1:100 mouse anti-human α-
SMA in 1% NSS overnight. Sections were then incu-
bated with a 1:300 biotinylated rabbit anti-mouse
(DAKO Corp.) for 1 hour followed by 45 minutes of
incubation with a 1:600 streptavidin/peroxidase con-
jugate (DAKO Corp.). Negative control sections were
run in parallel with nonimmune mouse or rabbit
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immunoglobulin diluted to the same concentration as
the primary antibodies. For fibronectin immunohis-
tochemistry, sections were digested with 0.4% pepsin
in 0.5N HCl before incubation with 1:2,000
fibronectin in 1% normal goat serum overnight. Sec-
tions were then incubated with a 1:300 biotinylated
goat anti-rabbit (DAKO Corp.) for 1 hour followed by
45 minutes of incubation with a 1:600
streptavidin/peroxidase conjugate (DAKO Corp.). All
sections were rinsed in 0.05 M acetate buffer (pH 5.0)
before development in an AEC chromogen substrate
for 15 minutes. All sections were counterstained in
Mayer’s hematoxylin for 2 minutes before mounting
with glycerine gelatine.
Hydroxyproline assay. Frozen lung samples were homog-
enized in deionized water, and hydroxyproline content
was determined by a colorimetric assay described previ-
ously (18). Data are calculated as micrograms of hydrox-
yproline per milligrams of lung tissue.
Statistical analysis. Data are shown as mean ± SEM. For
evaluation of group differences, we used the Student’s t
test. A P value less than 0.05 was considered significant.
Results
Expression of transgene protein and proinflammatory
cytokines in BAL fluid (IL-1β, TNF-α, and IL-6). We used an
ELISA specific for human IL-1β to detect and quantify
transgene human IL-1β in BAL fluid of infected rats.
Transgene hIL-1β was present in AdhIL-1β–treated ani-
mals as early as 2 days after infection and peaked by day
7 (4,733 ± 913 vs. 7.1 ± 1.4 pg/ml in AdDL70 control; P
< 0.008). The level of IL-1β in control animals was at the
detection limit of the ELISA. By day 14, hIL-1β levels
were markedly declined, but still significantly elevated
compared with control. After 3 weeks, transgene
cytokine was barely detectable, with concentrations sim-
ilar to control animals treated with PBS or control virus
AdDL70 (Figure 1a). Rat serum levels of hIL-1β were
higher by day 7 in AdhIL-1β–treated animals compared
with controls (826.8 ± 118.5 vs. 162.4 ± 60.5 pg/ml in
AdDL70; P < 0.02). To determine whether the back-
ground value of 160 pg/ml detected in rat serum was
due to rat IL-1β, samples were assayed for rat IL-1β by
rat-specific ELISA. In BAL fluid, endogenous (rat) IL-1β
appeared to be increased at 7 days (957.8 ± 425 vs. 84 ±
14 pg/ml in AdDL70) and was otherwise found at base-
line (<80 pg/ml) at all other times, but the day 7 change
did not reach statistical significance. When the rat IL-
1β assay was applied to serum, no differences were seen
in levels of rat IL-β between AdhIL-1β– and AdDL70-
treated animals.
The two other acute proinflammatory cytokines
determined in this study, TNF-α and IL-6, followed the
same time course as IL-1β with an earlier decline to nor-
mal. In AdhIL-1β–treated animals, TNF-α showed max-
imal expression by day 7 (84.5 ± 12.4 vs. 23.5 ± 1.5 pg/ml
in AdDL70 control; P < 0.02) and was returned to base-
line level by day 14 (Figure 1b). IL-6 was also maximally
present 7 days after infection with AdhIL-1β (329.2 ±
15.5 vs. 121.5 ± 35 pg/ml in AdDL70 control; P < 0.008)
and had returned to normal by day 14 (Figure 1c).
Serum acute-phase response. As an indication of circu-
lating IL-1 and effects on the liver, serum concentra-
tions of α1-cysteine protease inhibitor were determined
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Figure 1
Proinflammatory cytokines in BAL fluid. (a) Transgene human IL-
1β was elevated 2 days after injection of AdhIL-1β, was maximally
expressed after 7 days, and returned to baseline by day 14. Endoge-
nous TNF-α (b) and IL-6 (c) were upregulated parallel to hIL-1β
and returned to baseline concentration by day 14. In control ani-
mals treated with AdDL70, hIL-1β, TNF-α, and IL-6 were not dif-
ferent from PBS-treated rats. AP < 0.008 versus AdDL70 control; 
BP < 0.02 versus AdDL70 control.
Figure 2
Serum concentration of α1-cysteine protease inhibitor was maxi-
mally increased 7 days after injection of AdhIL-1β and returned to
baseline by day 14. Injection of control virus AdDL70 did not
cause elevated serum levels of α1-cysteine protease inhibitor. 
AP < 0.002 versus AdDL70 control.
to quantify the systemic acute-phase response. Rats
treated with AdhIL-1β had increased levels of cysteine
protease inhibitor 2 days after injection, peaking by day
7 (7.85 ± 0.59 vs. 1.32 ± 0.15 mg/ml in AdDL70 control;
P < 0.002), and returning to baseline by day 14 (Figure
2), mirroring changes to both IL-1 and IL-6 levels.
Acute effects of AdhIL-1β on the inflammatory response in the
lung. Intratracheal injection of AdhIL-1β resulted in a
dramatic acute inflammatory response in the lung. The
total amount of cells recovered in BAL fluid significant-
ly increased by day 7 in AdhIL-1β–treated animals com-
pared with control rats (Figure 3a). The vast majority of
inflammatory cells were neutrophils, which accounted
for almost 80% of cells in differential counts (Figure 3b).
Alveolar macrophages had morphological signs of acti-
vation, such as enlargement and increase of intracellular
vacuoles, and were predominant by day 14, when neu-
trophil counts were back to baseline. Other cell types
were not markedly increased in BAL fluid at any time
point. Control vector-treated animals showed normal
cellularity in BAL at these times. In the parenchyma,
inflammatory infiltrates were present as early as 2 days
after injection, predominantly in peribronchial areas,
and were most prominent by day 7 with patchy distri-
bution throughout the lungs (Figure 4, a and b). Infil-
trates were composed mainly of neutrophils and
macrophages (Figure 4, c and d). Some parts of the
inflamed sites showed marked tissue destruction and
disruption of alveolar architecture. The acute inflam-
matory response resolved after 2 weeks.
Expression of profibrotic cytokines in BAL fluid (PDGF and
total/active TGF-β). PDGF and total TGF-β in BAL fluid
were measured by ELISA. PDGF in BAL fluid was signif-
icantly increased only at day 14 after injection of AdhIL-
1β (397.2 ± 150 vs. 1,546 ± 265 pg/ml in AdDL70 control;
P < 0.04; Figure 5a). In contrast, TGF-β was elevated by
day 7 and was maximal 14 days after injection of AdhIL-
1β (380.9 ± 38.1 vs. 120.9 ± 39.6 pg/ml in AdDL70 con-
trol; P < 0.02; Figure 5b) at a time when IL-1 and other
cytokines had returned to baseline. TGF-β levels returned
to lower values by day 42, but were still significantly
increased compared with PBS-treated animals (P < 0.04).
Active TGF-β in BAL fluid was determined using a bioas-
say that measures luciferase activity induced by TGF-β
through PAI-I promoter in a transformed cell line. BAL
fluid contained significant amounts of active TGF-β at 7
and 14 days after injection of AdhIL-1β, equivalent to
approximately 100 pg/ml of recombinant human TGF-
β (P < 0.04 versus AdDL70 control; Figure 5c).
Chronic effects of AdhIL-1β and induction of fibrotic respons-
es in the lung. Transient overexpression of IL-1β induced
marked tissue injury and repair in the lung, leading to
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Figure 3
(a) Total cells retrieved by BAL were increased 7 and 14 days after injec-
tion of AdhIL-1β. The vast majority of cells at day 7 were neutrophils
(b), whereas alveolar macrophages accounted for the persistent
increase of total cells at day 14. Cell counts and differentials were nor-
mal by day 21. Seven days after injection, animals treated with control
virus AdDL70 had a slight, insignificant increase in total cell number.
Neutrophils were not elevated. AP < 0.01 versus AdDL70 control.
Figure 4
Lung histology in the first week after injection of AdhIL-1β showed
acute inflammatory reactions in the lungs, beginning in peri-
bronchial areas after 2 days (a). By day 7, inflammatory infiltrates
affected large parts of the lung (b). In some areas, the cellular infil-
trates completely filled alveoli while alveolar structures remained
intact. In other regions, they caused marked alveolar wall destruc-
tion (c). The inflammatory infiltrates consisted mainly of neu-
trophils and macrophages, reaching the airway lumen after pass-
ing bronchial mucosa (d). Hematoxylin and eosin staining; ×24 
(a and b); ×160 (c and d).
severe and progressive pulmonary fibrosis. Histological-
ly, an increase of pulmonary myofibroblasts and deposi-
tion of collagen in the interstitium was observed as early
as 14 days after intratracheal injection of AdhIL-1β.
Myofibroblasts were distributed throughout the tissue
in the interstitium and along alveolar walls, frequently
gathering and forming accumulations with similarities
to fibroblast foci seen in usual interstitial pneumonia in
humans (Figure 6). Immunohistochemistry and colla-
gen staining were used to demonstrate that these cells
were myofibroblasts (α-SMA; Figure 6b) and major pro-
ducers of collagen (Figure 6c) and other matrix compo-
nents such as fibronectin (Figure 6d). By day 21, lungs
showed extensive fibrotic areas and significant quanti-
ties of myofibroblasts and extracellular matrix (Figure 6,
e–g). The histological appearance of interstitial fibrosis
was unchanged at the latest observation point of the
study, assessed 60 days after initiation of tissue injury. At
that time, the quantity of myofibroblasts was markedly
reduced and few fibroblast foci were apparent.
Hydroxyproline content of lung homogenates was
determined to quantify the amount of collagen in the
tissue. The concentration of lung hydroxyproline was
elevated beginning 14 days after injection of AdhIL-1β,
confirming the histological observations, and was
steadily increased over the course of the experiment
(day 60: 5.03 ± 0.08 vs. 1.79 ± 0.17 µg/mg lung tissue in
control animals; P < 0.00001; Figure 7).
Effects of pulmonary overexpression of hIL-1β on other
organs. The liver showed a transient increase of intra-
cellular fat vacuoles by day 7, the time of maximal
expression of proinflammatory cytokines in BAL fluid
and acute-phase protein in serum. These changes dis-
appeared completely by day 42 without generation of
liver fibrosis. No obvious morphological changes were
observed in spleen, kidneys, or heart.
Discussion
We show in this study that transient overexpression of 
IL-1β in the epithelial cells of rodent lung using adenovi-
ral gene transfer induces acute inflammation with alveo-
lar tissue destruction resulting in progressive interstitial
fibrosis. Moreover, we demonstrate that this long-term
effect is coincident with sustained induction of the profi-
brotic cytokine TGF-β. To our knowledge, is the first
experimental model directly showing how acute tissue
injury in the lung, initiated by a highly proinflammatory
cytokine, IL-1β, converts to progressive fibrotic changes.
The IL-1 gene family is a group of cytokines involved
in a variety of acute and chronic lung diseases. The
three constituents are IL-1α, IL-1β, and IL-1RA. IL-1β
is one of the major extracellular proinflammatory
cytokines, acting often synergistically with TNF-α (1,
2). Several studies have described the important role of
IL-1 in acute lung injury. Short-time exposure to IL-1
by injection of recombinant IL-1 into rodent tracheas
leads to development of acute alveolar leakage and
neutrophil inflammation (19, 20). These experimental
findings are supported by data from human studies.
In patients with adult respiratory distress syndrome
(ARDS), IL-1 is elevated in BAL fluid and alveolar
macrophages (21–23). Although ARDS is a disorder
that leads to complete restoration of lung function in
a majority of cases, there is a substantial risk that pro-
gressive fibrosis develops (22, 24). IL-1β was shown to
be expressed in fibroproliferative areas in idiopathic
pulmonary fibrosis (6) and to be present in BAL fluid
of infants with chronic lung disease of prematurity
(25). Recent studies have demonstrated a potential
role for IL-1RA in pulmonary fibrosis. One study
showed a higher risk for fibrosing alveolitis in patients
with IL-1RA polymorphism and suggested a patho-
physiological role for unopposed IL-1 in this condi-
tion (26). Another study reported that patients with
chronic sarcoidosis have higher IL-1RA/IL-1β ratios in
BAL fluid compared with patients with radiographic
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Figure 5
Profibrotic cytokines in BAL fluid. (a) PDGF was increased 2 weeks
after injection of AdhIL-1β, 1 week after peak expression of proin-
flammatory cytokines, and returned to normal values by day 21. (b)
TGF-β also showed maximal expression after 2 weeks. By day 21, in
contrast to PDGF, concentration of TGF-β in BAL fluid was slightly
reduced compared with day 14. Increased TGF-β concentration was
measured for the entire course of the experiment up to day 60. (c)
The presence of bioactive TGF-β in BAL fluids of AdhIL-1β–treated
animals was demonstrated using an established bioassay (MLECs
with luciferase reporter gene, controlled by TGF-β–inducible pro-
moter PAI-1; for details see the text). AP < 0.04 versus AdDL70 con-
trol. BP < 0.02 versus AdDL70 control. CP < 0.04 versus PBS.
improvement, implying a predictive value for the
course of sarcoidosis (27, 28). In animal models in
which acute injury results in pulmonary fibrosis, e.g.,
using bleomycin, silica, or irradiation, the presence of
IL-1 was demonstrated by mRNA analysis and
immunohistochemistry (4, 5, 7). One study suggested
a major role of IL-1 in the generation of fibrosis by
showing beneficial effect of IL-1RA on the course of
bleomycin induced lung fibrosis (8).
In our study, animals were exposed to IL-1β in the lung
over a period of 7–10 days using adenoviral gene transfer
and responded with a vigorous acute inflammatory reac-
tion in the lungs. Predominant inflammatory cell types
involved in this process were neutrophil granulocytes and
macrophages, as was expected from previous studies. In
some pulmonary areas, inflammation was accompanied
by tissue destruction and disruption of alveolar architec-
ture. IL-1 is a known stimulus for the induction of other
proinflammatory cytokines, and we found significantly
increased concentrations of IL-6 and TNF-α in BAL fluid,
likely acting in concert with IL-1 to perpetuate inflam-
mation and subsequent events. We also showed that over-
expression of transgene human IL-1β appeared to induce
endogenous (rat) IL-1β in the lung at 7 days, but other-
wise there was no evidence of major involvement of
endogenous IL-1β in the response. The animals were sick
between days 4 and 8 after injection of AdhIL-1β, show-
ing symptoms of respiratory distress and systemic
involvement, such as fever and weight loss. Accordingly,
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Figure 6
Fibrogenic responses in the lung after intra-
tracheal injection of AdhIL-1β. (a) Numerous
fibroblast foci were observed in the lung tis-
sue 14 days after injection. Special staining
methods demonstrated that cells in these
foci were myofibroblasts (b, α-SMA
immunohistochemistry), and synthesized col-
lagen (c, Masson trichrome) and fibronectin
(d, immunohistochemistry). Major collagen
and fibronectin accumulation was noticed 3
weeks after injection of AdhIL-1β (e and f,
Masson trichrome and fibronectin immuno-
histochemistry), and myofibroblasts were
present in interstitial areas and along alveo-
lar walls (g, α-SMA immunohistochemistry).
The histological appearance of animals treat-
ed with control virus AdDL70 was normal (h,
Masson trichrome). ×160 (a–d); ×50 (e–h).
serum levels of the acute-phase protein α1-cysteine-pro-
tease inhibitor were elevated during this period. It is well
known that IL-1 induces a hepatic acute-phase reaction
with upregulated acute-phase protein (2). However, in
this model, the acute inflammatory response was fol-
lowed by extensive wound repair and progressive tissue
fibrosis. Beginning 2 weeks after initiation of the injury,
we noticed an increase of pulmonary collagen, both by
morphological analysis and by lung hydroxyproline con-
centrations. Lung collagen concentration steadily
increased during the course of the experiment, with the
highest level seen after 60 days. Myofibroblast-like cells
were observed in the tissue coincident with the first signs
of interstitial fibrosis. By day 14, numerous accumula-
tions of myofibroblasts were present, mainly in areas of
developing scars. Morphologically, the accumulations
had compelling similarities to fibroblast foci, a histolog-
ical feature characteristic for usual interstitial pneumo-
nia (see Figure 6). In usual interstitial pneumonia, fibrob-
last foci are areas where extracellular matrix is synthesized
and believed to be sites of ongoing tissue injury (29). The
fibroblast foci we observed in rat lung after overexpres-
sion of IL-1β showed marked presence of collagen and
fibronectin, supporting the hypothesis concerning the
role of fibroblast foci in humans.
Although IL-1 has always been considered to partici-
pate in tissue injury and repair, it has not been attributed
a major role in chronic disease to date. One likely reason
for this is controversial data about in vitro effects of 
IL-1. IL-1 was shown to stimulate collagen production
in skin fibroblasts (30), but conversely appears to reduce
ECM synthesis in lung fibroblasts (31). The effect on
fibroblast proliferation is also controversial (32). The
interference of IL-1 with prostaglandin synthesis may
affect its in vitro properties, because of strong anti-mito-
genic and antifibrotic influences of prostaglandins (33).
Although the direct effect of IL-1 on fibroblasts still has
to be determined, it is known that IL-1 is able to induce
cytokines and growth factors in vitro and in vivo (22).
Among those, PDGF and TGF-β are two key profibrotic
growth factors (10). In the present study, we measured
both PDGF and TGF-β in BAL fluid after administra-
tion of AdhIL-1β and found significantly elevated levels
peaking by day 14, 1 week after the maximal expression
of transgene IL-1β. Whereas PDGF returned to baseline
after 21 days, we found sustained expression of TGF-β
in BAL fluid, which was still increased 60 days after injec-
tion of AdhIL-1β and relates to the progressive fibrosis.
This observation complements our earlier findings
about transient overexpression of potentially profi-
brotic cytokines in the rodent lung. Among those, GM-
CSF, TNF-α, and TGF-β appear to play an important
role in the fibrotic tissue response (11–14). The main
differences between gene transfer models using these
cytokines and IL-1β on tissue inflammation and
remodeling in the lung are summarized in Table 1. The
extent and cellular composition of the acute inflam-
matory response of AdhIL-1β was similar to AdTNF-α.
However, in the AdTNF-α model we did not see the
extensive early alveolar destruction as in the AdhIL-1β
model, and the fibrotic response in the chronic stage
was marginal when compared with that of AdhIL-
1β–treated animals. In contrast to AdTNF-α and
AdhIL-1β, the experiments using active AdTGF-β1
showed virtually no acute inflammation and early tis-
sue damage, but resulted in dramatic and progressive
pulmonary remodeling and fibrosis. The delivery of
AdGM-CSF resulted in acute inflammation, some early
alveolar damage, and a marked fibrotic reaction, but
the extent of these changes was significantly less than
after the administration of AdhIL-1β. These observa-
tions show that IL-1β and TGF-β have a major, and
GM-CSF an intermediate, impact on chronic pul-
monary fibrosis, whereas TNF-α is not as effective
when transiently overexpressed by adenoviral gene
transfer. The summarized data (Table 1) suggest that
both the amount and duration of increased TGF-β in
the pulmonary environment are one of the reasons for
excessive remodeling and fibrosis. In the AdTGF-β
model, TGF-β was present at high levels (peak >50
ng/ml) for approximately 10 days, followed by pul-
monary collagen accumulation 1 week after peak
expression. After administration of AdGM-CSF,
endogenous TGF-β was increased for 11 week (maxi-
mal 600 pg/ml), resulting in marked but not excessive
fibrosis, whereas AdTNF-α increased TGF-β just
twofold above control vector (150 pg/ml), with only
minor evidence of fibrosis. The concentration of TGF-
β in BAL fluid after AdhIL-1β was similar to the
AdGM-CSF model, but was delayed (peak expression of
400 pg/ml after 21 days) and appeared to increase
through day 60. In addition to the ability to induce
endogenous TGF-β, the potential to cause early alveo-
lar destruction appears to effect the profibrotic prop-
erties of individual cytokines.
It is also important to realize that transient overex-
pression of IL-1β, TGF-β, GM-CSF, or TNF-α in the
lung induced the development of chronic inflammation
and fibrosis. This phenomenon was restricted to the
lung, despite considerable systemic involvement during
the acute phase of the models. In particular, IL-1β
induced systemic effects previously associated with this
cytokine including the hepatic acute-phase response,
fever and cachexia. However, the fibrosis was restricted
to the lung, the tissue site where TGF-β was generated,
suggesting that the process of fibrogenesis is tissue-spe-
cific and limited. This also suggests that therapeutic
intervention would best target the local event and
involve less the systemic effects of many cytokines that
play both pathological as well as physiological roles.
The complex transcriptional, translational, and
post-translational regulation of the IL-1 gene family
offers opportunity for pharmacological intervention.
The presence of a natural antagonist, IL-1RA, is a
unique feature in cytokine biology and overexpres-
sion of IL-1RA could be beneficial in diseases associ-
ated with IL-1 (1–3). Earlier clinical trials with IL-
1RA that focused on sepsis and ARDS have shown
some promising, but yet unconfirmed, results (34,
35). To our knowledge, there is no systematic analy-
sis of the clinical benefit of IL-1RA in fibroprolifera-
tive disease. Another target for drug development is
the IL-1 receptor. Two receptors for IL-1 are known
and bind to IL-1α, IL-1β, and IL-1RA with similar
affinity: type I receptor mediates the signal trans-
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Table 1
Effect of the profibrotic cytokines IL-1β, TNF-α, GM-CSF, and TGF-β
on acute tissue injury and remodeling in the rodent lung after delivery
by adenoviral gene transfer
Inflammation Alveolar TGF-β Fibrosis
destruction in BALF
AdIL-1β +++ ++ 400 pg/ml +++
AdTNFαA +++ +/– 150 pg/ml +
AdGM-CSFB ++ + 600 pg/ml ++
AdTGFβ1C – – >50 ng/ml +++
ARef. 12; Bref. 13; Cref. 11.
Figure 7
Animals treated with AdhIL-1β showed a progressive increase of lung
hydroxyproline concentration past day 21 after injection. AP < 0.01
versus AdDL70 control. BP < 0.01, CP < 0.001 versus PBS control.
duction together with the receptor accessory protein,
whereas type II receptor does not transfer a signal
and acts as a sink for IL-1 (36). It was recently shown
that human lung epithelial cells do not express suffi-
cient type II receptor and thus lack the ability to
downregulate IL-1β activity (37). Hence, overexpres-
sion of type II receptor in pulmonary epithelium, e.g.,
using gene transfer, could be a valuable treatment
option in lung diseases associated with increased
local concentrations of IL-1β.
These data indicate that IL-1β plays an immediate
and direct role in pulmonary tissue injury and repair.
They show that IL-1β is a potent inducer of TGF-β, and
suggest that at least a part of its profibrotic effects is
mediated through this growth factor. IL-1β should be
considered a valid target for therapeutic intervention
in diseases associated with fibrosis and tissue remodel-
ing, such as pulmonary fibrosis, chronic asthma, liver
cirrhosis, and renal fibrosis.
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